Expression Profiles of Circulating microRNAs in South African Type 2 Diabetic Individuals on Treatment

Cecil J. Weale, Don M. Matshazi, Saarah F. G. Davids, Shanel Raghubeer, Rajiv T. Erasmus, Andre P. Kengne, Glenda M. Davison and Tandi E. Matsha

1SAMRC/CPUT/Cardiometabolic Health Research Unit, Department of Biomedical Sciences, Faculty of Health and Wellness Science, Cape Peninsula University of Technology, Cape Town, South Africa, 2National Health Laboratory Service (NHLS), Division of Chemical Pathology, Faculty of Health Sciences, University of Stellenbosch, Cape Town, South Africa, 3Non-Communicable Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa, 4Department of Medicine, University of Cape Town, Cape Town, South Africa

Aim: The influence of disease duration and anti-diabetic treatment on epigenetic processes has been described, with limited focus on interactions with microRNAs (miRNAs). miRNAs have been found to play key roles in the regulation of pathways associated with type 2 diabetes mellitus (T2DM), and expression patterns in response to treatment may further promote their use as therapeutic targets in T2DM and its associated complications. We therefore aimed to investigate the expressions of circulating miRNAs (miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p) in newly diagnosed and known diabetics on anti-diabetic treatment, in South Africa.

Methods: A total of 1254 participants with an average age of 53.8 years were included in the study and classified according to glycaemic status (974 normotolerant, 92 screen-detected diabetes and 188 known diabetes). Whole blood levels of miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p were quantitated using RT-qPCR. Expression analysis was performed and compared across groups.

Results: All miRNAs were significantly overexpressed in subjects with known diabetes when compared to normotolerant individuals, as well as known diabetics vs. screen-detected (p < 0.001). Upon performing regression analysis, of all miRNAs, only miR-182-5p remained associated with the duration of the disease after adjustment for type of treatment (OR: 0.127, CI: 0.018–0.236, p = 0.023).

Conclusion: Our findings revealed important associations and altered expression patterns of miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p in known diabetics on anti-diabetic treatment compared to newly diagnosed individuals. Additionally, miR-182-5p expression decreased with increasing duration of T2DM. Further studies are, however, recommended to shed light on the involvement of the miRNA in insulin signalling and glucose homeostasis, to endorse its use as a therapeutic target in DM and its associated complications.

Keywords: South Africa, miR-30a-5p, miR-1299, miR-182-5p, miR-126-3p, treatment, type 2 diabetes
INTRODUCTION

MicroRNAs (miRNAs) are a family of short, noncoding RNA molecules, averaging 22 nucleotides in length, responsible for regulating gene expression by repressing the translation of messenger RNA (mRNA) molecules, as well as by destabilization of the mRNA molecules (Zhou et al., 2015; O’Brien et al., 2018). Since their discovery, miRNAs have been found to play key roles in the regulation of pathways associated with various diseases, including cancers (Liu et al., 2017; Zhang et al., 2019), cardiovascular diseases (Maciejak et al., 2018; Zhu et al., 2019), and diabetes mellitus (DM; Zampetaki et al., 2010; Massaro et al., 2019; Wang et al., 2019). These small noncoding transcripts have been shown to modulate insulin biosynthesis, pancreatic β-cell development and survival, as well as glucose and lipid metabolism (Mao et al., 2013). Investigations have illustrated altered expression levels of miRNAs, such as miR-30a-5p and miR-126-3p across different glycemic states, suggesting their potential use as novel biomarkers for early detection of diabetes (Qin et al., 2017; Jiménez-Lucena et al., 2018a). With increased exploration of human miRNAs in the setting of disease, strategies for diagnosis have been the primary focus. However, the focus has progressively extended toward assessing miRNA expression levels and treatment of disease (Walayat et al., 2018).

The interactions of medications, such as metformin with epigenetic processes, have been detailed, including influences in histone modifications, as well as DNA methylation. DNA methylation-induced changes have been the most widely addressed, with reduced methylation due to metformin treatment reported at the insulin gene promoter in a beta-cell line cultured using high glucose concentrations (Ishikawa et al., 2015). Similarly, reduced methylation of transporter genes (SLC22A1, SLC22A3 and SLC47A1) was reported in the livers of diabetics on metformin therapy, compared to diabetics not receiving anti-diabetic medication (García-Calzón et al., 2017). Although not as widely investigated, key evidence surrounding the associations between DM therapies and miRNA expression also exists, with reports of metformin-induced alterations in miRNA expression in diabetic humans and mice, due to increased levels of DICER enzymes, which are essential in miRNA processing (Noren Hooten et al., 2016). Additionally, plasma miR-222 has been linked with insulin action, and positive associations have been identified with type 2 diabetes mellitus (T2DM; Coleman et al., 2013). In two separate studies, both insulin infusion and metformin treatment led to reduced circulating levels of the miRNA in patients with T2DM (Coleman et al., 2013; Ortega et al., 2014). In the same way, miRNA expressions aid in the mediation of these processes in disease development and progression, and changes in their expression in response to anti-diabetic treatment may pave the way for new therapeutic strategies. In view of this, we aimed to investigate the expression of a panel of miRNAs, previously demonstrating altered expressions (Matsha et al., 2018), in a South African population with T2DM, receiving either metformin treatment, insulin and/or both. Furthermore, we intended to assess the expression levels in association with the duration of T2DM since the date of first diagnosis. Our findings in addition to other investigations focused on miRNA dysregulation in T2DM development and progression may lay the foundation for new targets for disease management and therapy.

MATERIALS AND METHODS

Ethical Approval

The study was approved by the Research Ethics Committees of the Cape Peninsula University of Technology and Stellenbosch University (NHREC: REC—230, 408–014 and N14/01/003, respectively). Ethical clearance for this sub-study was sought from and granted by the Cape Peninsula University of Technology Ethics Committee (CPUT/HW-REC 2019/H3). The study was conducted in accordance with the Declaration of Helsinki, and all participants voluntarily signed written informed consent after all the procedures were fully explained in their language of choice.

Study Design

This study was cross-sectional in design, and data were obtained from the ongoing Cape Town Vascular and Metabolic Health (VMH) study, as previously described (Kengne et al., 2017). Data collection took place between April 2014 and November 2016, involving only South Africans from Cape Town. In a total of 1989 participants that were enrolled in the VMH study, 1,254 met the inclusion criteria for this study, including 92 with T2DM; Coleman et al., 2013). In two separate studies, both insulin infusion and metformin treatment led to reduced circulating levels of the miRNA in patients with T2DM (Coleman et al., 2013; Ortega et al., 2014). In the same way, miRNA expressions aid in the mediation of these processes in disease development and progression, and changes in their expression in response to anti-diabetic treatment may pave the way for new therapeutic strategies. In view of this, we aimed to investigate the expression of a panel of miRNAs, previously demonstrating altered expressions (Matsha et al., 2018), in a South African population with T2DM, receiving either metformin treatment, insulin and/or both. Furthermore, we intended to assess the expression levels in association with the duration of T2DM since the date of first diagnosis. Our findings in addition to other investigations focused on miRNA dysregulation in T2DM development and progression may lay the foundation for new targets for disease management and therapy.

MATERIALS AND METHODS

Ethical Approval

The study was approved by the Research Ethics Committees of the Cape Peninsula University of Technology and Stellenbosch University (NHREC: REC—230, 408–014 and N14/01/003, respectively). Ethical clearance for this sub-study was sought from and granted by the Cape Peninsula University of Technology Ethics Committee (CPUT/HW-REC 2019/H3). The study was conducted in accordance with the Declaration of Helsinki, and all participants voluntarily signed written informed consent after all the procedures were fully explained in their language of choice.

Study Design

This study was cross-sectional in design, and data were obtained from the ongoing Cape Town Vascular and Metabolic Health (VMH) study, as previously described (Kengne et al., 2017). Data collection took place between April 2014 and November 2016, involving only South Africans from Cape Town. In a total of 1989 participants that were enrolled in the VMH study, 1,254 met the inclusion criteria for this study, including 92 with T2DM
protein (usCRP) was measured by Latex Particle immunoturbidimetry. Serum γ-glutamyltransferase (gamma GT-S) was measured using the International Federation of Clinical Chemistry and Laboratory Medicine standardized reagents on a Beckman AU (Beckman Coulter, South Africa). Serum cotinine was determined using the Competitive Chemiluminescent (Immulite 2000, Siemens, South Africa).

Total RNA Isolation
Total RNA, including miRNAs, was isolated from 3 ml of whole blood, which was collected in Tempus RNA tubes that were stored at −80°C before RNA isolation (Applied Biosystems). The MagMAX™ for Stabilized Blood Tubes RNA Isolation Kit was used to perform the RNA extraction, as per manufacturer’s specifications (Life Technologies, South Africa). RNA purity and integrity were then evaluated using a nanodrop (Nanodrop Technologies, Wilmington, United States), and only samples with a concentration > 15 ng/ml, and an OD (optical density) ratio $A_{260}/A_{280} > 1.8$, were deemed adequate for further processing.

cDNA Conversion and Reverse Transcriptase qPCR
Subsequent RNA samples were then converted to cDNA, using the TaqMan Advanced miRNA cDNA Synthesis Kit, following manufacturer guidelines (Applied Biosystems, Thermo Fisher Scientific, South Africa). This protocol converts RNA to cDNA in four separate reactions, namely, poly(A) tailing, adapter ligation, reverse transcription, and finally a miR-Amp reaction. The poly(A) tailing reaction involved the addition of a 3’-adenosine tail to the miRNA, catalysed by the enzyme poly(A) polymerase. 2 μl of each RNA sample was aliquoted into individual wells of a MicroAmp™ Optical 96-Well Reaction Plate. A reaction mix was then prepared with the poly(A) tailing reagents, as per the manufacturer's protocol, after which, 3 μl transferred into each well of the plate. The reaction plate was sealed with adhesion film, mixed and centrifuged. Following that, the plate was incubated in a QuantStudio™ 7 Flex Real-Time PCR System (Applied Biosystems, Life Technologies Corporation, Johannesburg, South Africa). The following settings were used to configure the QuantStudio™ 7 Flex – polyadenylation at 37°C for 45 min, then a stop reaction at 65°C for 10 min and finally an infinite hold step at 4°C. Following incubation, the plate was removed and the adapter ligation step commenced. The miRNA with poly(A) tails underwent adaptor ligation at their 5’ end. In accordance with manufacturer guidelines, a new reaction mix was prepared with the adapter ligation reagents, following that 10 μl of the mix was transferred into each well of the reaction plate containing the poly(A) tailing reaction product. After sealing the plate, it was briefly mixed, centrifuged and incubated – reverse transcription at 42°C for 15 min, then a stop reaction at 85°C for 5 min, followed by an infinite hold at 4°C. The miR-Amp reaction step then followed, in which universal forward and reverse primers amplified the number of cDNA templates present in each sample. The reaction mix was prepared as per manufacturer specifications and 45μl transferred into a new 96-well reaction plate. A total volume of 5 μl of the reverse transcription reaction product from the previous reaction step was added to each well of the new plate containing the miR-Amp reaction mix and incubation commenced at the following cycling conditions – enzyme activation at 95°C for 5 min, for 1 cycle, then denaturation at 95°C for 3 s, for 14 cycles, thereafter annealing/extension at 60°C for 30 s, for 14 cycles, a stop reaction at 99°C for 10 min, for 1 cycle, and a hold step at 4°C, for 1 cycle. After successful completion of cDNA synthesis, samples were stored at −20°C until required for reverse transcriptase qPCR (RT-qPCR) analysis.

Prior to performing RT-qPCR, resultant cDNA samples were diluted 1:10 for optimum quantitative analysis. Thereafter, miRNA expression levels were evaluated, as per manufacturer instructions, using pre-designed TaqMan Advanced miRNA Assay primers for the investigated miRNAs: miR-30a-5p (assay ID: 479448_mir; catalogue number: A25576), miR-1299 (assay ID: 478696_mir; catalogue number: A25576), miR-182-5p (assay ID: 477935_mir; catalogue number: A25576), miR-30e-3p (assay ID: 478388_mir; catalogue number: A25576) and miR-126-3p (assay ID: 477887_mir; catalogue number: A25576; Applied Biosystems, Thermo Fisher Scientific, Johannesburg, South Africa). Data were obtained as Ct values and normalized to an endogenous control, miR-16-5p (assay ID: 477860_mir; catalogue number: A25576; Applied Biosystems, Johannesburg, Thermo Fisher Scientific, South Africa). Minimal differences were observed in the expression of the endogenous control between varied glycaemic groups, validating its stability, particularly between newly diagnosed vs. treated diabetes (Weale et al., 2020). The $2^{-\Delta\text{Ct}}$ method was used to evaluate the miRNA expression level in each sample, whilst the $2^{\Delta\text{Ct}}$ value was used as the measure of the miRNA expression in each sample analysed compared with the control sample (Livak and Schmittgen, 2001).

Statistical Analysis
Analysis of data was $+$performed using SPSS v.25 (IBM Corp., 2011). The data were tested for normality using Normal Q-Q Plots. The results for categorical variables were presented as count (and percentages), whilst continuous variables were presented as mean (and standard deviation) for normally distributed variables, and median with 25th–75th percentiles was presented for skewed distributions. For comparison between glucose tolerance groups, analysis of the (ANOVA) and the Kruskal-Wallis test were used for continuous variables, whilst the chi-square test was used to assess categorical variables. Spearman’s partial correlations, adjusted for age, sex and body mass index (BMI), were performed to assess the relationship
between miRNA expression and other variables. Furthermore, multivariate regression analysis was conducted in order to assess differences in miRNA expression with duration of disease. Various models were used, which were Model 1: Crude; Model 2: adjusted for age and sex; Model 3: adjusted for age, sex and type of medication; and Model 4: adjusted for adjusted for age, sex and type of medication, serum total cholesterol (cholesterol-S), usCRP, log gamma GT-S and log S-creatinine. A value of $p < 0.05$ was used to characterize statistically significant results.

**RESULTS**

**Basic Characteristics of Participants**
As illustrated in Table 1, participants were 53.8 years old on average, with the majority being female (72.7%), and most being normotolerant ($n = 974$). As expected, glycaemic parameters (fasting blood glucose, 2-h blood glucose and HbA1c) were significantly higher in the screen-detected and known diabetes groups vs. the normotolerant group ($p < 0.001$). Body mass index (BMI), waist circumference and hip circumference were significantly higher in both screen-detected DM and known DM, compared to the normotolerant group ($p < 0.001$). Additionally, lipid variables, such as triglycerides-S and cholesterol LDL-S, increased significantly across the glycaemic groups ($p < 0.001$), whilst cholesterol HDL-S exhibited a significant reduction from the normotolerant group through to the known DM group ($p = 0.039$). Both systolic blood pressure and diastolic blood pressure measurements were observed to increase significantly across the glycaemic groups (all of which, $p < 0.001$). Inflammatory markers usCRP and gamma GT-S were significantly higher in the diabetic groups in contrast to the normotolerant group, with reduced levels in known DM vs. screen-detected. Of the known diabetics on treatment, 165 (87.8%) were on oral medication, whilst 23 (12.2%) were on either both oral and/or insulin treatment.

**Relative miRNA Expression**
All miRNAs were significantly overexpressed in subjects with known diabetes compared to normotolerant individuals ($p < 0.001$), and additionally, a significant elevation was observed in known diabetics vs. screen-detected ($p < 0.001$; Figure 1). miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p were all significantly upregulated in screen-detected DM compared to the normotolerant group ($p \leq 0.013$), with the exception of miR-30e-3p ($p = 0.145$), and miR-30a-5p exhibited the most significant increase in expression ($p = 0.001$) between the two groups.

**Comparisons Between miRNA Expression With Treatment and Duration of Disease**
The median duration of condition in individuals with known diabetes and on anti-diabetic treatment was 8 years. Although not significant, all other miRNAs with the exception of miR-182-5p were increased in individuals who had had diabetes for over 8 years with miR-30e-3p and miR-126-3p nearing significance, $p \leq 0.095$. miR-182-5p was significantly reduced in individuals who had had diabetes for over 8 years, $p = 0.033$ (Table 2). No significant differences were observed between the expression of miRNAs and the type of treatment, that is, oral or combination of oral and/or insulin, $p > 0.05$ (Table 2).

**Partial Spearman’s Correlation Coefficients Adjusted for Age, Sex and Body Mass Index**
Spearman’s non-parametric correlations, adjusted for age, sex and BMI, were conducted in order to identify significant associations between the expression of the selected miRNAs and other parameters (Table 3). All miRNAs observed significant positive correlations with each other (all, $p \leq 0.002$), with the exception of miR-1299 and miR-126-3p ($p = 0.075$). Correlations with glucose indices revealed significant negative correlations between miR-30a-5p and miR-30e-3p with fasting blood glucose ($r = -0.308$, $p = 0.045$ and $r = -0.315$, $p = 0.040$, respectively). Likewise, miR-30e-3p demonstrated a significant negative correlation with HbA1c, $r = -0.318$, $p = 0.037$. The other target miRNAs, however, did not observe noteworthy correlations with any of the aforementioned glycaemic indices. With respect to obesity markers, only miR-30a-5p and miR-30e-3p correlated significantly and negatively, with triglycerides-S ($r = -0.319$, $p = 0.037$ and $r = -0.371$, $p = 0.014$, respectively), whilst the remaining miRNAs demonstrated no such associations. All miRNAs exhibited significant negative correlations with cholesterol HDL-S (all of which, $p \leq 0.046$), whilst none demonstrated any significant links with cholesterol LDL-S. Although, with respect to cholesterol-S, all miRNAs, with the exception of miR-1299, showed notable negative correlations, all of which were $p \leq 0.036$. Correlations with known inflammatory markers revealed significant negative associations between all miRNAs and both usCRP and gamma GT-S (all, $p \leq 0.046$); miR-1299, however, did not observe any significant correlation with gamma-GT-S. Additionally, all miRNAs demonstrated significant correlations with markers of kidney function, namely, S-creatinine, MDRD eGFR (Modification of Diet in Renal Disease estimated glomerular filtration rate) and CKD-EPI eGFR (Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate), all of which were $p \leq 0.047$.

**Multivariate Regression Analysis of miRNAs for the Duration of Diabetes**
The log miRNA $2^{-\Delta C_{\text{t}}}$ was used to perform multivariate regression analysis, in order to demonstrate the relationships between the expression of the investigated miRNAs and the duration of T2DM (Table 4). The expressions of miRNA-1,299, miR-182-5p and miR-126-3p were associated with duration of diabetes when the model was adjusted for age and sex [odds ratio (OR) $\geq 0.076$, 95% confidence interval (CI): 0.001–0.151, $p \leq 0.046$]; however, after adjustment for type of treatment,
### TABLE 1 | Characteristics of participants according to diabetic status.

|                | Normal (n = 974) | Screened DM (n = 92) | Known DM (n = 188) | Value of p  |
|----------------|------------------|----------------------|-------------------|-------------|
| miR-30a-5p (ΔCt) | 0.0252 ± 0.0549  | 0.0494 ± 0.0916      | 0.1577 ± 0.2512    | <0.001      |
| miR-30a-5p (2-ΔCt) | 0.0086 (0.0023;0.0262) | 0.0169 (0.0041;0.0576) | 0.0664 (0.0110;1.1858) | <0.001      |
| miR-1299 (ΔCt)   | 0.0033 ± 0.0108  | 0.0042 ± 0.009       | 0.0264 ± 0.062     | <0.001      |
| miR-1299 (2-ΔCt) | 0.0007 (0.0001;0.0023) | 0.0009 (0.0003;0.0036) | 0.0046 (0.0012;0.0202) | <0.001      |
| miR-182-5p (ΔCt) | 1.457 ± 2.0279   | 2.4347 ± 4.742       | 8.979 ± 11.1365    | <0.001      |
| miR-182-5p (2-ΔCt) | 0.7994 (0.3065;1.7988) | 1.3223 (0.3966;2.4185) | 4.6079 (1.3219;13.0158) | <0.001      |
| miR-30e-3p (ΔCt) | 0.0047 ± 0.0071  | 0.0056 ± 0.0087      | 0.0291 ± 0.0478    | <0.001      |
| miR-30e-3p (2-ΔCt) | 0.0019 (0.0006;0.0062) | 0.0023 (0.0006;0.0079) | 0.0119 (0.0025;0.041) | <0.001      |
| miR-126-3p (ΔCt) | 1.0375 ± 0.9964  | 1.6141 ± 1.324       | 7.2226 ± 7.1824    | <0.001      |
| miR-126-3p (2-ΔCt) | 0.7251 (0.2917;1.5107) | 1.4188 (0.4402;2.4671) | 4.7558 (1.4091;10.7017) | <0.001      |
| **Age (years)**  | 45.22 ± 15.3     | 58.15 ± 10.62        | 57.88 ± 11.97      | <0.001      |

**Sex, n (%)**

- Female: 688 (70.6) vs. 73 (79.3) vs. 151 (80.3) p = 0.008
- Male: 286 (29.4) vs. 19 (20.7) vs. 37 (19.7) p = 0.001

**Body mass index (kg/m²)**

- 24 (7.5) vs. 31.5 (8.0) vs. 30.7 (6.4) p < 0.001

**Waist circumference (cm)**

- 87.9 ± 16.5 vs. 100.2 ± 15.5 vs. 99.3 ± 16.5 p < 0.001

**Education level, n (%)**

- <7 years: 271 (28) vs. 39 (43.3) vs. 75 (40.3) p < 0.001
- ≥7 years: 698 (72) vs. 51 (66.7) vs. 111 (69.7) p < 0.001

**Tobacco use, n (%)**

- Non-smoker: 393 (42.1) vs. 58 (66.7) vs. 128 (70.3) p < 0.001
- Current smoker: 540 (57.9) vs. 29 (33.3) vs. 54 (29.7) p < 0.001

**Alcohol use, n (%)**

- Non-drinker: 645 (66.5) vs. 76 (83.5) vs. 161 (86.6) p < 0.001
- Current drinker: 325 (33.5) vs. 15 (16.5) vs. 25 (13.4) p = 0.024

Cholesterol HDL-S, serum high-density lipoprotein cholesterol; cholesterol LDL-S, serum low-density lipoprotein cholesterol; cholesterol-S, serum total cholesterol; usCRP, ultrasensitive C-reactive protein; gamma GT-S, serum gamma-glutamyl transferase; S-creatinine, serum creatinine; MDRD eGFR, Modification of Diet in Renal Disease estimated glomerular filtration rate; and CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate. *data represented as median (25th–75th percentile). **value of p between normal group and screen-detected diabetes only.

only the expression of miR-182-5p remained independently associated with the duration of the disease (OR: 0.127, CI: 0.018–0.236, p = 0.023). Upon further adjustment for usCRP, log gamma GT-S and log S-creatinine, miR-182-5p expression retained significance in its association with duration of T2DM (OR: 0.145, CI: 0.034–0.255, p = 0.011); moreover, miR-30e-3p as well as miR-126-3p also exhibited notable associations [(OR: 0.103, CI: 0.007–0.199, p = 0.036) and (OR: 0.145, CI: 0.020–0.270, p = 0.024), respectively].

**DISCUSSION**

In this study, the expressions of circulating miRNAs (miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p) were investigated in newly diagnosed and known diabetic individuals on treatment. Our data show that these miRNAs are differentially expressed in individuals with diabetes, as well as between newly diagnosed and those on treatment. All target miRNAs correlated significantly with each other, with the exception of miR-1299.
and miR-126-3p. Correlations were illustrated between miR-30a-5p and miR-30e-3p with fasting blood glucose and HbA1c, as well as with triglycerides-S. Furthermore, all miRNAs, except miR-1299, correlated significantly with HDL-cholesterol and serum total cholesterol, as well as with inflammatory markers (usCRP and \( \gamma \)-glutamyltransferase), with similar

**FIGURE 1** | Relative expression of miRNAs according to glycaemic status using log miRNA \( 2^{-\Delta \Delta Ct} \). Normalization was relative to the expression of miR-16-5p. Data are shown as median (25th–75th percentile). (A) miR-30a-5p; (B) miR-1299; (C) miR-182-5p; (D) miR-30e-3p; and (E) miR-126-3p.

**TABLE 2** | Comparisons between miRNA expression with treatment type and duration of disease.

| Types of medication | Duration of disease |
|--------------------|---------------------|
| Both/Insulin       | Oral                | value of p | <8 years | \( \geq \)8 years | value of p |
| miR-30a-5p (2\(^{-\Delta \Delta Ct}\)) | 0.0641 (0.0292; 0.2787) | 0.0664 (0.0098; 0.184) | 0.280 | 0.0581 (0.0069; 0.1787) | 0.0607 (0.0182; 0.1906) | 0.567 |
| miR-1299 (2\(^{-\Delta \Delta Ct}\)) | 0.0048 (0.0015; 0.0233) | 0.0045 (0.0011; 0.0196) | 0.665 | 0.0041 (0.0006; 0.0207) | 0.0075 (0.0015; 0.0243) | 0.155 |
| miR-182-5p (2\(^{-\Delta \Delta Ct}\)) | 7.4965 (2.183; 14.1241) | 4.5773 (1.1516; 12.9642) | 0.427 | 3.2669 (1.0255; 10.3437) | 6.4257 (2.2623; 13.4441) | 0.033 |
| miR-30e-3p (2\(^{-\Delta \Delta Ct}\)) | 0.0098 (0.003; 0.0375) | 0.0128 (0.0025; 0.0431) | 0.765 | 0.0073 (0.0019; 0.0295) | 0.0128 (0.0034; 0.0437) | 0.065 |
| miR-126-3p (2\(^{-\Delta \Delta Ct}\)) | 4.1712 (1.765; 9.1078) | 4.8205 (1.3649; 10.9543) | 0.673 | 3.8398 (1.3521; 8.4545) | 5.749 (2.0933; 11.674) | 0.095 |
TABLE 3 | Partial Spearman’s correlation coefficients adjusted for age, sex and body mass index (BMI).

| Adjusted for age, BMI and sex | miR-30a-5p (2^{ΔCt}) | miR-1299 (2^{ΔCt}) | miR-182-5p (2^{ΔCt}) | miR-30e-3p (2^{ΔCt}) | miR-126-3p (2^{ΔCt}) |
|------------------------------|-----------------------|---------------------|----------------------|----------------------|-----------------------|
|                            | r                     | value of p           | r                     | value of p           | r                     | value of p           |
| miR-30a-5p (2^{ΔCt})        | 1.000                 | –                   | 0.497                 | 0.001                | 0.739                 | <0.001               |
|                            | 0.497                 | 0.001               | 1.000                 | –                   | 0.582                 | <0.001               |
| miR-1299 (2^{ΔCt})          | 0.739                 | <0.001              | 0.582                 | <0.001              | 1.000                 | –                   |
|                            | 0.668                 | <0.001              | 0.488                 | 0.001               | 0.668                 | <0.001               |
| miR-182-5p (2^{ΔCt})        | 0.668                 | <0.001              | 0.488                 | 0.001               | 1.000                 | –                   |
|                            | 0.587                 | <0.001              | 0.488                 | 0.001               | 0.562                 | <0.001               |
| Waist circumference         | –0.078                | 0.618               | –0.002                | 0.988               | –0.134                | 0.392               |
|                            | –0.076                | 0.628               | –0.000                | 0.998               | –0.130                | 0.406               |
| Hip circumference (cm)      | –0.173                | 0.266               | –0.164                | 0.293               | –0.227                | 0.143               |
| Systolic blood pressure (mmHg) | –0.155            | 0.320               | –0.149                | 0.340               | –0.206                | 0.186               |
| Diastolic blood pressure (mmHg) | –0.308          | 0.045               | –0.207                | 0.183               | –0.227                | 0.144               |
| Glucose (Fasting) (mg/dL)   | –0.308                | 0.045               | –0.207                | 0.183               | –0.227                | 0.144               |
| HbA1c (%)                   | –0.260                | 0.093               | –0.247                | 0.110               | –0.247                | 0.111               |
| Insulin Fasting (mIU/L)     | –0.171                | 0.273               | –0.181                | 0.245               | –0.200                | 0.198               |
| Triglycerides-S (mmol/L)    | –0.319                | 0.037               | –0.281                | 0.068               | –0.297                | 0.053               |
| Cholesterol HDL-S (mmol/L)  | –0.381                | 0.012               | –0.306                | 0.046               | –0.326                | 0.033               |
| Cholesterol LDL-S (mmol/L)  | –0.327                | 0.053               | –0.280                | 0.069               | –0.281                | 0.051               |
| Cholesterol-S (mmol/L)      | –0.385                | 0.011               | –0.293                | 0.056               | –0.320                | 0.036               |
| usCRP (mg/dL)               | –0.388                | 0.010               | –0.306                | 0.046               | –0.320                | 0.036               |
| Gamma GT-S (IU/L)           | –0.385                | 0.011               | –0.294                | 0.056               | –0.320                | 0.037               |
| S-Creatinine (µmol/L)       | –0.390                | 0.007               | –0.303                | 0.039               | –0.328                | 0.025               |
| MDRD eGFR (ml/min)          | –0.383                | 0.011               | –0.306                | 0.046               | –0.318                | 0.038               |
| CKD-EPI eGFR (ml/min)       | –0.382                | 0.011               | –0.306                | 0.047               | –0.316                | 0.039               |

Cholesterol HDL-S, serum high-density lipoprotein cholesterol; cholesterol LDL-S, serum low-density lipoprotein cholesterol; cholesterol-S, serum total cholesterol; usCRP, ultrasensitive C-reactive protein; gamma GT-S – serum gamma-glutamyl transferase; S-creatinine – serum creatinine; MDRD eGFR, Modification of Diet in Renal Disease estimated glomerular filtration rate; and CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate.
associations exhibited with kidney function indicators, MDRD eGFR and CKD-EPI eGFR. We observed that the duration of the disease is the most determining factor in the expression of these miRNAs. For instance, miR-182-5p was significantly decreased in individuals who had diabetes for over 8 years, but no such differences were observed when anti-diabetic treatment was taken into account. Moreover, miR-1299, miR-182-5p and miR-126-3p were significantly associated with T2DM in regression analysis adjusted for age and sex, but when medication was included in the model, that association was lost for miR-1299 and miR-126-3p and only retained by miR-182-5p.

Advances in whole-genome sequencing as well as epigenome profiling technologies have contributed toward accelerated growth in research aimed at unveiling the roles of epigenetics in human disease (Hawkins et al., 2010; Laird, 2010; Afshin and Ghaderian, 2013; Koperski et al., 2017) particularly the roles of miRNAs in DM (Zampetaki et al., 2010; Karolina et al., 2011; Jiménez-Lucena et al., 2018a). miRNAs target-specific messenger RNA (mRNA), hindering translation of the subsequent proteins the mRNA encode for (Bartel, 2009), as such, understanding these potential targets and the resultant knock-on effects of altered miRNA expression, is essential in unravelling the intricate subclinical molecular mechanisms that drive disease development.

For instance, a previous rat-based study demonstrated miR-30a-5p to be a mediator of beta-cell dysfunction-induced glucotoxicity, by suppressing the expression of Beta2/NeuroD, a gene responsible for regulating pancreatic beta-cell maintenance and insulin gene transcription (Noguchi et al., 2005; Kim et al., 2013). The investigation further established that an overexpression of the miRNA led to pancreatic beta-cell dysfunction (Kim et al., 2013). Additionally, in a follow-up study spanning 5 years, Jiménez-Lucena and co-workers assessed plasma miRNAs, via RT-qPCR, in non-diabetic patients, in order to ascertain whether the combined use of these miRNAs with clinical and biochemical measures was more beneficial in predicting type 2 diabetes (Jiménez-Lucena and co-workers, 2018b). Nine dysregulated miRNAs were identified, which when added to HbA1c, yielded acceptable predictive values in early detection of type 2 diabetes, one of which was miR-30a-5p. Elevated expression of the miRNA was found to be associated with increased risk of T2DM development, with higher levels of miR-30a-5p observed in participants diagnosed with T2DM in the first year of follow-up, in comparison with those diagnosed in later years. These findings were consistent with ours, in that we also observed marked miR-30a-5p expression in newly diagnosed diabetics (Bijkerk et al., 2015). However, the cross-sectional nature of our investigation thwarted us in accurately assessing the effects of prolonged disease on its expression.

Another promising candidate, miR-126-3p, has been heralded as a potential biomarker for early detection of dysglycaemia (Zampetaki et al., 2010; Zhang et al., 2013; Rezk et al., 2016) and its role as a regulator of angiogenesis is known (Wang et al., 2008). A recent report has shown insulin receptor substrate 1 (IRS1) as a target for miR-126-3p, demonstrating overexpression of the miRNA mediating marked reduction in IRS1 in smooth muscle cells. IRS1 plays an essential role in insulin signalling in hyperglycaemic states; thus, a reduction in its expression negatively impacts glucose metabolism (Trygggestad, 2019). miR-126-3p expression has also been investigated in associations with complications associated with long-term diabetes, such as diabetic kidney disease (DKD; KDIGO, 2013; Bijkerk et al., 2015; Assmann et al., 2018). Bijkerk et al. (2015) determined significantly increased expression of circulating miR-126-3p in the plasma of subjects with diabetic nephropathy (with a mean duration of diabetes of 29 years), in comparison with those without (Bijkerk et al., 2015). In accordance with these findings, a separate systematic review, which aimed at identifying studies comparing miRNA expression in persons with DKD and diabetics without the complication, showed that of the studies included, miR-126-3p was found to be overexpressed in either whole blood, plasma, urine or kidney tissue in patients with DKD (Assmann et al., 2018). These reports may offer a plausible explanation for our findings of altered miR-126-3p expression in diabetic states (both screen-detected and long-term diabetes), as well as the significant associations demonstrated with known measures of renal dysfunction. Although, in our sample, the median duration of diabetes was less, the findings of Bijkerk et al. (2015) corroborate the moderate associations we observed between dysregulated miR-126-3p and duration.

### TABLE 4 | Univariate regression analysis of miRNAs for the duration of diabetes.

| B       | Std error | 95% Confidence Interval (CI) | value of p |
|---------|-----------|-------------------------------|------------|
| Log miR-30a-5p (2−ΔCt) |          |                               |            |
| Model 1 | −0.021    | 0.037                         | −0.094     | 0.053 | 0.581 |
| Model 2 | 0.023     | 0.036                         | −0.047     | 0.094 | 0.511 |
| Model 3 | 0.029     | 0.040                         | −0.049     | 0.108 | 0.464 |
| Model 4 | 0.049     | 0.041                         | 0.032      | 0.130 | 0.234 |
| Log miR-1299 (2−ΔCt) |          |                               |            |
| Model 1 | 0.058     | 0.040                         | −0.022     | 0.138 | 0.151 |
| Model 2 | 0.076     | 0.038                         | 0.001      | 0.151 | 0.046 |
| Model 3 | 0.064     | 0.027                         | −0.010     | 0.138 | 0.088 |
| Model 4 | 0.068     | 0.038                         | −0.007     | 0.142 | 0.075 |
| Log miR-182-5p (2−ΔCt) |          |                               |            |
| Model 1 | 0.078     | 0.040                         | 0.000      | 0.156 | 0.051 |
| Model 2 | 0.101     | 0.037                         | 0.029      | 0.174 | 0.007 |
| Model 3 | 0.127     | 0.065                         | 0.018      | 0.236 | 0.023 |
| Model 4 | 0.145     | 0.056                         | 0.034      | 0.255 | 0.011 |
| Log miR-30e-3p (2−ΔCt) |          |                               |            |
| Model 1 | 0.040     | 0.045                         | −0.050     | 0.130 | 0.384 |
| Model 2 | 0.070     | 0.042                         | −0.013     | 0.153 | 0.097 |
| Model 3 | 0.086     | 0.047                         | −0.008     | 0.179 | 0.072 |
| Model 4 | 0.103     | 0.048                         | 0.007      | 0.199 | 0.036 |
| Log miR-126-3p (2−ΔCt) |          |                               |            |
| Model 1 | 0.083     | 0.043                         | −0.012     | 0.177 | 0.086 |
| Model 2 | 0.102     | 0.044                         | −0.014     | 0.189 | 0.023 |
| Model 3 | 0.119     | 0.062                         | −0.003     | 0.241 | 0.066 |
| Model 4 | 0.145     | 0.063                         | 0.020      | 0.270 | 0.024 |

Model 1 Crude; Model 2: adjusted for Age and Sex; Model 3: adjusted for Age, Sex, Type of Medication; and Model 4: adjusted for Age, Sex, Type of Medication, Cholesterol-S, uACRF, log Gamma GT-S and log S-creatinine.
of diabetes. Moreover, Prattichizzo et al aimed to identify specific miRNA signatures from plasma extracellular vesicles (EVs) of diabetic individuals with and without complications (Prattichizzo et al., 2021b). These EVs are minute membranous particles that have been shown to transport miRNAs, with postulations that they may elucidate inter-tissue communications in disease states, through the expression patterns of the miRNA signatures they shuttle (Guay and Regazzi, 2017; Xiao et al., 2019). Prattichizzo and colleagues identified miRNAs influenced by diabetes, one of which was miR-126-3p; however, the miRNA did not witness significant differential expression in diabetics with complications (mean duration of disease being 20 years). In our study, miR-126-3p expression observed similar susceptibility to dysglycaemic states; furthermore, although we do not report data pertaining to diabetic complications, we did however demonstrate moderate relationships between long-term T2DM (median duration of 8 years) and its expression. In a similarly study, which included a treatment aspect, significantly decreased miR-126-3p levels were found in untreated diabetics as well as diabetics on metformin treatment, in comparison with levels in the control group (Ghai et al., 2019). We, however, did not witness any notable associations when treatment was accounted for. In light of these findings, it is relevant to mention that whole blood, which was the starting sample in our study, contains collective miRNAs from circulating plasma-specific EVs, blood-cell-derived miRNAs, as well as those bound to carriers such as HDL and RNA-binding proteins (Prattichizzo et al., 2021b). Pre-analytical centrifugation of samples is necessary for retrieving plasma from whole blood, and this may influence the expression profiles of miRNAs, due to the removal of blood-cell-specific miRNAs (Felekki and Papanephytou, 2020). All things considered, although whole blood provides better yields of miRNA, caution should still be approached when cross-comparing studies, due to the expression variations between tissues (Prattichizzo et al., 2021b).

Reports have also described the involvement of candidate miRNA, miR-182, in regulating glucose homeostasis, chiefly by targeting FOXO1 (Karolina et al., 2011; Zhou et al., 2014; Zhang et al., 2016). Mammalian cells express four FOXO variants, namely, FOXO1, FOXO3, FOXO4 and FOXO6, of which FOXO1 is the most abundantly expressed in liver, adipose tissue as well as in pancreatic beta-cells (Kitamura et al., 2002). FOXO1 is vital in regulating pancreatic beta-cell replication and differentiation, as well as maintenance in states of metabolic stress (Kitamura, 2013). Furthermore, FOXO1 is involved in stimulating hepatic glucoseogenesis in states of hypoglycaemia via the phosphoinositide-3-kinase/protein kinase B (PI3K/Akt) signalling pathway, whilst in hyperglycaemia, insulin signalling via insulin, like growth factor-1 (IGF-1) and its receptor (IGF-1R), stimulates PI3K/Akt-dependent phosphorylation of FOXO1, leading to subsequent suppression of glucoseogenesis (Tsuchiya and Ogawa, 2017). In this regard, in early stages of dysglycaemia, increased levels of miR-182 in individuals with prediabetes compared to those with newly diagnosed diabetes have been linked with attempted inhibition of hepatic glucoseogenesis, whilst pathological downregulation in diabetes promoted gluconeogenesis (Karolina et al., 2011). With respect to the direct impact of long-term hyperglycaemia and treatment, there is a paucity of information relating to miR-182-5p expression. Albeit, in a cancer-related study, Li et al. (2012) aimed at evaluating miRNAs connected with the anti-tumour effects of metformin in human gastric cancer cells. Upregulation of miR-182 was revealed in the cultured cells and cancer tissues treated with metformin when compared to untreated cells (Li et al., 2012). In our study, we did not observe any influences of anti-diabetic treatment (oral metformin and/or insulin) on the expression of the selected miRNAs, but rather marked differences with duration of the disease, especially with respect to miR-182-5p. miR-182-5p has, however, demonstrated links with diabetes-related complications, such as DKD, which is a common complication of diabetes (Ming et al., 2019). Ming and co-workers illustrated overexpression of miR-182-5p in the podocytes of individuals with DKD, as opposed to non-diabetic controls, alluding that this increased expression was linked to a reduction in CD2-associated protein, which is crucial in podocyte apoptosis and subsequent development of chronic kidney disease in diabetic persons (Ming et al., 2019). Ming et al. (2019) did not include information pertaining to the duration of diabetes in their study subjects, however, their findings corroborating the associations we found between miR-182-5p expression and key indicators of kidney function. Based on literature, our study mirrors previous findings in that miR-182-5p expression is indeed altered in hyperglycaemic states, though the underlying molecular mechanisms remain unclear. Furthermore, in light of the scarcity of reports pertaining to long-term T2DM and miR-182-5p expression, we have shown that the time span of disease in known diabetics has more of an influence on the expression of the miRNA, as opposed to treatment. This justifies the need for further research ventures, in order to ascertain these associations, particularly in diabetics with complications.

This is the first study of its kind to be conducted in an African setting, and findings may contribute toward curbing the increasing burden of T2DM in Africa. The study was, however, limited by the disproportionate representation of normotolerant vs. screen-detected diabetics and known diabetics on treatment. Additionally, the cross-sectional nature of the study limits accurate evaluation of anti-diabetic induced epigenetic changes; hence, longitudinal studies are advised. The absence of information pertaining to diabetes-associated complications in known diabetics hampered our ability to comprehensively assess the influences of long-term diabetes on miRNA expression, as such, it would be more beneficial to include such data in future. A further limitation was that the expression of the target miRNAs was assessed, without predicting and measuring potential target mRNA levels. Hence, future recommendations would be to explore and measure potential target miRNA levels to elucidate the knock-on effects of altered miRNA expression on downstream proteins. This would aid in more accurate comparisons of the underlying molecular interplays between controlled and uncontrolled diabetics.
CONCLUSION

Our study has revealed important associations and altered expression patterns of miR-30a-5p, miR-1299, miR-182-5p, miR-30e-3p and miR-126-3p in individuals with diabetes on anti-diabetic treatment compared to newly diagnosed cases. Furthermore, we show that miR-182-5p in particular decreases with increasing duration of T2DM. Longitudinal and functional investigations are recommended to elucidate the involvement of the miRNA in insulin signalling and glucose homeostasis, to endorse its use as a therapeutic target in DM and its associated complications.

DATA AVAILABILITY STATEMENT

The datasets presented in this article are not readily available because of the terms of consent to which participants agreed, but are available from the principal investigator of the main study on reasonable request. Requests to access the datasets should be directed to TM, matshat@cput.ac.za.

ETHICS STATEMENT

This study involving human participants was reviewed and approved by the Research Ethics Committees of the Cape Peninsula University of Technology and Stellenbosch University (NHREC: REC—230,408–014 and N14/01/003, respectively). Ethical clearance for this sub-study was sought from and granted by the Cape Peninsula University of Technology Ethics Committee (CPUT/HW-REC 2019/H3). The patients/participants provided their written informed consent to participate in this study.

REFERENCES

Afieh, S. S. A., and Ghaderian, S. M. H. (2013). The role of microRNAs in cardiovascular disease. Int. J. Mol. Cell. Med. 2, 50–57.
Alberti, K. G. M. M., and Zimmet, P. Z. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 15, 539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
Assmann, T. S., Recamonde-Mendoza, M., de Souza, B. M., Bauer, A. C., and Crispim, D. (2018). MicroRNAs and diabetic kidney disease: systematic review and bioinformatic analysis. Mol. Cell. Endocrinol. 477, 90–102. doi:10.1016/j.mce.2018.06.005
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell 136, 215–233. doi:10.1016/j.cell.2009.01.002
Bijkerk, R., Duijs, J. M. G. J., Khairoun, M., Ter Horst, C. J. H., Van Der Pol, P., Mallat, M. J., et al. (2015). Circulating MicroRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation. Am. J. Transplant. 15, 1081–1090. doi:10.1111/ajt.13072
Coleman, C. B., Lightell, D. J., Moss, S. C., Bates, M., Parrino, P. E., and Woods, T. C. (2013). Elevation of miR-221 and-222 in the internal mammary arteries of diabetic subjects and normalization with metformin. Mol. Cell. Endocrinol. 374, 125–129. doi:10.1016/j.mce.2013.04.019

AUTHOR CONTRIBUTIONS

All authors contributed significantly to this project. CW: wrote the first draft, experimental procedures, data analysis and interpretation. DM: experimental procedures, data analysis and interpretation. SD: recruitment and screening of cohort, statistical analysis and interpretation of data. SR: interpretation of data, editing and revising it for intellectual content. RE: conception, interpretation of the data, revising it for intellectual content and final approval of the version to be published. AK: conception, interpretation of the data, revising it for intellectual content and final approval of the version to be published. GD: conception and design of the study, analysis and interpretation of the data, revising it for intellectual content and final approval of the version to be published.

FUNDING

This research project was supported by grants from the South African Medical Research Council (SAMRC), with funds from National Treasury under its Economic Competitiveness and Support Package (MRC-RFA-UFP-01-2013/VMH Study), South African National Research Foundation (SANRF) grant no. 115450). Any opinions, findings, conclusions or recommendations expressed in this article are those of the authors, and the SAMRC and/or SANRF do not accept any liability in this regard.

ACKNOWLEDGMENTS

We thank the Bellville South community and their community Health Forum for supporting the study.
Jiménez-Lucena, R., Camargo, A., Alcalá-Díaz, J. F., Romero-Baldonado, C., Luque, R. M., Van Ommen, B., et al. (2018a). A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORIOPREV study. *Exp. Mol. Med.*, 50, 1–12. doi: 10.1038/s41619-018-0159-x

Jiménez-Lucena, R., Rangel-Záñiga, O. A., Alcalá-Díaz, J. F., López-Moreno, J., Roncoro-Ramos, I., Molina-Abril, H., et al. (2018b). Circulating miRNAs as predictive biomarkers of type 2 diabetes mellitus development in coronary heart disease patients from the CORIOPREV study. *Mol. Ther. Nucleic. Acids.*, 12, 146–157. doi: 10.1016/j.omtn.2018.05.002

Karolina, D. S., Armsgam, A., Tavintharan, S., Wong, M. T. K., Lim, S. C., Sum, C. F., et al. (2011). MicroRNA-144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. *PLoS One* 6:e22839. doi: 10.1371/journal.pone.0022839

Kidney Disease Improving Global Outcomes (KDIGO) (2013). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney. Int.*, 3, 1–150. doi: 10.1038/ki.2013.243

Kengne, A. P., Erasmus, R. T., Levitt, N. S., and Matsha, T. E. (2017). Alternative indices of glucose homeostasis as biochemical diagnostic tests for abnormal glucose tolerance in an African setting. *Prim. Care. Diabetes.* 11, 119–131. doi: 10.1177/1751733217701044

Kim, J. W., You, Y. H., Jung, S., Suh-Kim, H., Lee, I. K., Cho, J. H., et al. (2013). MicroRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models. *Diabetologia* 56, 847–855. doi: 10.1007/s00125-012-2812-8

Kitamura, T. (2013). The role of FOXO1 in diabetic nephropathy. *Kidney. Int.*, 9, 615–623. doi: 10.1038/ni.2013.15

Kitamura, T., Nakae, J., Kitamura, Y., Kido, Y., Biggs, W. H., Wright, C. V. E., et al. (2005). BETA2/NeuroD protein can be transduced into cells due to an N-terminal myristylation. *Diabetes*, 54, 2859–2866. doi: 10.2337/diabetes.54.10.2859

Noren Hooten, N., Martin-Montalvo, A., Dluzen, D. F., Zhang, Y., Bernier, M., and at al. (2016). Metformin-mediated increase in Dicer1 regulates microRNA expression and cellular senescence. *Aging Cell* 15, 572–581. doi: 10.1111/acel.12469

Ortega, F. J., Mercader, J. M., Moreno-Navarrete, J. M., Rovira, O., Guerra, E., Esteve, E., et al. (2014). Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. *Diabetes. Care.* 37, 1375–1383. doi: 10.2337/dc13-1847

Pattichizou, F., De Nigris, V., Sabbatinielli, J., Giuliani, A., Caño, C., Párrizas, M., et al. (2021a). CD31+ extracellular vesicles from patients with type 2 diabetes shuttle a microRNA signature associated with cardiovascular complications. *Diabetes* 70, 240–254. doi: 10.1037/dbt0000390

Prattichizzo, F., Matacchione, G., Giuliani, A., Sabbatinielli, J., Oliveri, F., de Candia, P., et al. (2021b). Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. *Theranostics* 11, 1031. doi: 10.7150/thno.51605

Qi, L.-L., An, M.-X., Liu, Y.-L., Xu, H.-C., and Lu, Z.-Q. (2017). MicroRNA-126: a promising novel biomarker in peripheral blood for diabetic retinopathy. *Int. J. Ophtalmol.* 10.1002/jio.2017.04.05

Rezk, N. A., Sabbah, N. A., and Saad, M. S. S. (2016). Role of microRNA-126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. *Hum. Biol.* 89, 452–458. doi: 10.1016/j.humbiol.2015.12.005

Tryggestad, J. B. (2019). 188-LB: MicroRNA-126-3p impacts insulin Signaling in smooth muscle cells. *Diabetes* 68:188-LB. doi: 10.2337/db19-188-LB

Tsukihara, K., and Ogawa, Y. (2017). Forkhead box class O family member proteins: The biology and pathophysiological roles in diabetes. *J. Diabetes Investig.* 8, 726–734. doi: 10.1111/jdi.12651

Walyat, A., Yang, M., and Xiao, D. (2018). “Therapeutic Implication of miRNA in Human Disease,” in *Antisense Therapy*. eds. S. Sharad and S. Kapur (London, UK: IntechOpen).

Wang, S., Aurora, A. R., Johnson, B. A., Qi, X., McAnally, J., Hall, J. I., et al. (2008). The endothelial-specific microRNA microRNA-126 governs vascular integrity and angiogenesis. *Dev. Cell.* 15, 261–271. doi: 10.1016/j.devcel.2008.07.002

Wang, J., Wang, G., Liang, Y., and Zhou, X. (2019). Expression profiling and clinical significance of plasma microRNAs in diabetic nephropathy. *J. Diabetes Res.* 2013:5204394. doi: 10.1155/2019/5204394

Weale, C. J., Matszahi, D. M., Davids, S. F. G., Raghubeer, S., Erasmus, R. T., Kengne, A. P., et al. (2020). Circulating mir-30a-5p and mir-182-5p in prediabetes and screen-detected diabetes mellitus. *Diabetes Metab. Syndr.* 13, 5037–5047. doi: 10.1016/j.dsx.2020.05.002

Xiao, Y., Zheng, L., Zou, X., Wang, J., Zhong, J., and Zhong, T. (2019). Extracellular vesicles in type 2 diabetes mellitus: key roles in pathogenesis, complications, and therapy. *J. Extracell. Vesicles.* 8:1625677. doi: 10.1080/20030789.2019.1625677

Zampetaki, A., Kiechl, S., Drozdzov, I., Willeit, P., Mayr, U., Prokopi, M., et al. (2010). Plasma microRNA profiling reveals loss of endothelial miR-126 and other MicroRNAs in type 2 diabetes. *Circ. Res.* 107, 810–817. doi: 10.1161/CIRCRESAHA.110.226357

Zhang, D., Li, Y., Yao, X., Wang, H., Zhao, L., Jiang, H., et al. (2016). miR-182 regulates metabolic homeostasis by modulating glucose utilization in muscle. *Cell Rep.* 16, 757–768. doi: 10.1016/j.celrep.2016.06.040

Zheng, et al. (2019). MiR-1299 functions as a tumor suppressor to inhibit the proliferation and metastasis of prostate cancer by targeting NEK2. *Eur. Rev. Med. Pharmacol. Sci.* 23, 530–538. doi: 10.26355/eurrev_201901_16658

Zhang, T., Lv, C., Li, L., Chen, S., Liu, S., Wang, C., et al. (2013). Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. *Biomed. Res. Int.* 2013, 1076167. doi: 10.1155/2013/761617

Zhou, J. Y., Xu, B., and Li, L. (2015). A new role for an old drug: metformin targets microRNAs in treating diabetes and cancer. *Drug Dev. Res.* 76, 263–269. doi: 10.1002/ddr.21265
Zhu, L., Chen, T., Ye, W., Wang, J. Y., Zhou, J. P., Li, Z. Y., et al. (2019). Circulating miR-182-5p and miR-5187-5p as biomarkers for the diagnosis of unprotected left main coronary artery disease. *J. Thorac. Dis.* 11, 1799–1808. doi: 10.21037/jtd.2019.05.24

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Weale, Matshazi, Davids, Raghubeer, Erasmus, Kengne, Davison and Matsha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.